ABACUS (ABL) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Abacus Global Management, Inc. on Behalf of Abacus Stockholders and Encourages Investors to Contact the Firm GlobeNewswire August 12, 2025 If you purchased or acquired stock in Abacus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or […]

NEW YORK CITY, NY / ACCESS Newswire / August 12, 2025 / WHY: New York, N.Y., August 12, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ:VRA) resulting from allegations that Vera Bradley may have issued materially misleading business

NEW YORK, NY / ACCESS Newswire / August 12, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=161118&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 12, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=161117&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK CITY, NY / ACCESS Newswire / August 12, 2025 / WHY: New York, N.Y., August 12, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ:WGS) resulting from allegations that GeneDx may have issued materially misleading business information

The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the DIO

(NASDAQ:TWFG), – Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million –– Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million –– Organic Revenue Growth Rate* of 10.6% for the quarter –– Net income of $9.0 million for the quarter –– Adjusted

TWFG Announces Second Quarter 2025 Results GlobeNewswire August 12, 2025 – Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million –– Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million –– Organic Revenue Growth Rate* of 10.6% for the quarter –– Net

— The sale resulted in aggregate gross proceeds of c. USD50 million Frontier TopCo Partnership, L.P. (the “Selling Stockholder”), an affiliate of the funds known as EQT Infrastructure III and EQT Infrastructure IV, is pleased to announce the completion of the sale (the “Sale”) of c. 1.5 million shares of common stock of Kodiak Gas

Robbins LLPreminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. https://mma.prnewswire.com/media/1321386/Robbins_LLP_Logo.jpg For more information,